Search results
Showing 91 to 105 of 166 results for fibrosis
Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.
Selective internal radiation therapy for primary hepatocellular carcinoma (IPG460)
Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.
View recommendations for IPG460Show all sections
Sections for IPG460
Read biographies of the members of our quality standards advisory committee.
Read biographies of the members of our quality standards advisory committee.
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic
Topic prioritisation
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 18 November 2026
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]
In development Reference number: GID-TA11678 Expected publication date: 19 August 2026
Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)
Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.
for people with cystic fibrosis? Any explanatory notes(if applicable) Why this is important- People with cystic fibrosis...
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Discontinued Reference number: GID-TA11041
Find out what guidance is being considered for development
assessment and monitoring of changes in pulmonary status in people with cystic fibrosis? Any explanatory notes(if applicable) Why this...
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.